Anti-Human IL-3R alpha/CD123 & CD3 epsilon Bispecific Reference Antibody (Flotetuzumab, RUO) (HB714046)

Name: Anti-Human IL-3R alpha/CD123 & CD3 epsilon Bispecific Reference Antibody (Flotetuzumab, RUO)
Brand: abinScience
SKU: HB714046
Price: 320 USD
Availability: InStock

Даташит Поделиться продуктом Копировать информацию

Цена(USD):

Спецификация:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Количество:

Свяжитесь с нами

Обзор
Изображения
Ссылки
Даташит
SDS

Обзор

Каталожный номер	HB714046
Описание	Flotetuzumab (HB714046) is a research-grade recombinant antibody targeting CD123. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Реактивность видов	Human
Применения	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Хозяинский вид	Human
Клоональность	Monoclonal
Изотип	VH-VL-VH'-VL'
Система экспрессии	Mammalian cells
Цель	IL-3R subunit alpha, IL-3 receptor subunit alpha, CD123, Interleukin-3 receptor subunit alpha, IL3R, IL-3R-alpha, IL3RA, IL-3RA, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain
Уровень эндотоксинов	< 10 EU/mg
Чистота	>95% purity as determined by SDS-PAGE.
Очистка	Purified by Nickel column.
Номер доступа	P26951 & P07766
Форма	Liquid
Буфер хранения	0.01M PBS pH 7.4 Пожалуйста, обратитесь к конкретной информации о буфере в печатной версии даташита или в индивидуальном сертификате качества (COA) для партии.
Устойчивость и хранение	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Альтернативные названия	Bispecific, MGD-006, MGD006, RES234, S80880, 1664355-28-5
Фон	Vibecotamab (XmAb®14045) is a tumor-targeted antibody that contains both a CD123 binding domain and a cytotoxic T-cell binding domain (CD3) in a Phase 1 clinical trial for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies. An XmAb Bispecific Fc domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on vibecotamab. CD123 is highly expressed on AML cells and leukemic stem cells, and it is associated with poorer prognosis in AML patients. Engagement of CD3 by vibecotamab activates T cells for highly potent and targeted killing of CD123-expressing tumor cells.
Примечание	For research use only. Not suitable for clinical or therapeutic use.